Establishment of Ideal IV Sedative Regimen for Successful Fiberoptic Bronchoscopy in Assessing the Site, Severity of Sleep Apnea Syndrome

Not Applicable

Completed

• Conditions: Sleep Apnea Syndrome
• Interventions: Drug: dexmedetomidine infusion rate, 0.5 mcg/kg/hr; Drug: dexmedetomidine infusion rate, 1.0 mcg/kg/hr

• Registration Number: NCT02148432
• Lead Sponsor: Yonsei University

Brief Summary

Venous thromboembolism(VTE) is the third most common cardiovascular complication among hospitalized patients, and can even cause death. VTE often occurs in intensive care patients and there had been many efforts to prevent such complication. The American College of Chest Physicians (ACCP) had published evidence-based clinical practice guideline for VTE prophylaxis.

This study focuses on how VTE prophylaxis is being performed in both medical and surgical ICUs in a single University hospital, and sees the differences in such prophylactic patterns.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2014-05-19
• Study First Submitted: 2014-05-22
• Study First Submitted QC: 2014-05-27
• Study First Posted: 2014-05-28
• Primary Completion: 2016-04-29
• Study Completion: 2016-04-29
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-23
• Last Update Posted: 2017-01-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

1. 20-60 years old patients with ASA class I-II
2. Scheduled for drug induced sleep endoscope after diagnosed with sleep apnea syndrome

Read More

Exclusion Criteria

1. Patients having hearing difficulties, taking any CNS related medication, history of any adverse drug reaction, Glasgow coma scale < 15
2. Patients with severe cardiopulmonary dysfunction
3. Patients refusal

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
dexmedetomidine 0.5 mcg/kg/hr	dexmedetomidine infusion rate, 0.5 mcg/kg/hr	-
dexmedetomidine 1.0 mcg/kg/hr	dexmedetomidine infusion rate, 1.0 mcg/kg/hr	-

Primary Outcome Measures

Name	Time	Method
Desaturation rate	Baseline from 5 min after remifentanil TCI start, 10 min after dexmedetomidine loading start, every 5 min until surgeon can do endoscopy successfully, to immediately after endoscopy	SpO2 \< 90% (checked by pulse oximetry)

Trial Locations

Locations (1)

Department of Anesthesiology and Pain Medicine, Severance Hospital, Yonsei University College of Medicine; 🇰🇷 Seoul, Korea, Republic of